You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Cyclosporine (Neoral®)

Find drug coverage information and forms for cyclosporine, by funding source.

What type of drug coverage does the patient have?

Private Insurance

  • Provide cyclosporine DIN 02247074 to patient to explore coverage through private insurer and if any special authorization forms are required.

Ontario Drug Benefit (ODB) and OHIP+

  • Cyclosporine is not covered by ODB limited use code for GN indication. Through the Exceptional Access Program (EAP), it will be considered for nephrotic syndrome but the provider must clearly indicate why cyclophosphamide and/or prednisone are not being used or if failed.
  • Complete Exceptional Access Program (EAP) form (see sidebar for form).

Trillium Drug Program (TDP)

  • Enrol into TDP if not already enrolled.
  • Complete Exceptional Access Program (EAP) form (see sidebar for form).

Federal Non-Insured Health Benefits (NIHB) Program

  • Prior approval required. Have community pharmacy contact Drug Exception Centre for Exception Drugs Request Form to be sent to prescriber’s office.  Send completed form to Drug Exception Centre.

Interim Federal Health Program (IFHP)

  • Medication coverage and duration of coverage vary depending on each individual’s case.
  • Contact IFHP with cyclosporine DIN 02247074 for assessment of coverage

No Medication Coverage

  • Enrol into TDP.
  • If enrolling in TDP, refer to TDP.

Disclaimer: The information contained herein (“Information”) is intended for informational purposes only, and no warranty as to its accuracy is provided or implied. The Information was collected from third party sources and is subject to change without notice. Cancer Care Ontario (CCO) makes no warranty that the Information is current. The Information is intended for use by healthcare professionals, subject to their clinical and/or professional judgment, to advise patients of drug funding options that may be available to them. Do not act or rely upon the Information without exercising your independent judgment or seeking the advice of a qualified professional. Anyone using the Information does so at his or her own risk. The drug funding options described herein are managed and funded by third parties, not by CCO. Please direct any inquiries to the applicable agency/entity who manages the drug funding option. CCO does not recommend or endorse the use of any drug or treatment method described herein.